IN BRIEF: GSK secures accelerated approval of Nelkarmi in US

GSK PLC - London-based pharmaceutical company - US Food & Drug Administration grants accelerated approval to Nelkarmi, also known as neladalkib, for adults with previously-treated advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. The approval was based on trial results that confirmed an overall response rate of 49% with a duration of response of six or more months in 76% of responders and 12 plus months in 52% of responders. The approval came before the original FDA target action date of November 27 and Nelkarmi previously received FDA's breakthrough therapy and orphan drug designations.

Chief Scientific Officer Tony Wood says: "Nelkarmi is our second new medicine approved in lung cancer this year. It was designed to help address key challenges of ALK-positive non-small cell lung cancer through its broad coverage of ALK resistance mutations, ability to cross the blood-brain barrier and high target selectivity. ALK-positive patients are often younger and can remain on treatment for years, making effective and tolerable new treatment options especially important, and we are pleased to bring this innovation to patients in the US."

Current stock price: 1,912.50 pence

12-month change: up 7.0%

By Elijah Dale, Alliance News senior reporter Asia-Pacific

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center